AstraZeneca-linked studies: OlympiaN, ZEAL and CHIO3 post results; two new studies registered

This week's AstraZeneca-linked registry activity includes results from three studies, one of which ended early, and two newly listed programs.

• The OlympiaN study (NCT05498155), a Phase II trial of neoadjuvant olaparib monotherapy and olaparib plus durvalumab combination therapy in BRCA-mutated, HER2-negative early-stage breast cancer, posted results on 2026-09-25. The trial enrolled 50 participants and its primary outcome was the pCR rate of olaparib monotherapy and olaparib plus durvalumab combination therapy, assessed by central pathology review, with pCR defined as no invasive residual disease in the breast and axillary lymph nodes following neoadjuvant therapy. AstraZeneca is the lead sponsor.
• The ZEAL study (NCT05516498), a two-part Phase IIa/b trial of zibotentan combined with dapagliflozin, and dapagliflozin monotherapy, versus placebo in patients with cirrhosis and features of portal hypertension, posted results on 2026-09-25. The study was terminated earlier than planned due to a sponsor decision, after enrolling 205 participants. Its primary outcome was absolute change in hepatic venous pressure gradient from baseline to week 6 in Part A. AstraZeneca is the lead sponsor.
• The CHIO3 trial (NCT04062708), testing neoadjuvant chemotherapy plus durvalumab followed by surgery, radiation, and adjuvant durvalumab in operable stage IIIA/B non-small cell lung cancer, posted results on 2026-09-23. The study enrolled 38 participants and its primary goal was to raise N2 nodal clearance to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from a historical rate of 30% for platinum doublet chemotherapy alone¹ in patients with potentially resectable stage IIIA/B (N2) NSCLC. AstraZeneca is a collaborator; Alliance Foundation Trials, LLC is the lead sponsor.
• A new observational study (NCT07833046) will track patients with multiple myeloma who previously received "GC012F Injection" CAR-T therapy, following specific adverse events, overall survival, progression-free survival, duration of response, objective response rate, replication-competent lentivirus, and CAR gene insertion site testing for 15 years from infusion². The study is not yet recruiting, with an estimated enrollment of 40 participants. AstraZeneca Global R&D units in China and Beijing are collaborators; RenJi Hospital is the lead sponsor.
• A new Phase II study (NCT07832630) will test saruparib, described as an experimental PARP inhibitor³, in patients with platinum-sensitive, HRDsig-positive solid tumors identified via the FoundationOne CDx assay. The study is not yet recruiting, plans to enroll 124 participants, and its primary endpoint is overall response rate in Cohort A³. AstraZeneca is a collaborator; the Abramson Cancer Center at Penn Medicine is the lead sponsor.